We have located links that may give you full text access.
Pituitary function before and after surgery for nonfunctioning pituitary adenomas - Data from the Swedish Pituitary Register.
European Journal of Endocrinology 2023 August 9
OBJECTIVE: Data on pre- and postoperative pituitary function in nonfunctioning pituitary adenomas (NFPA) are not consistent. We aimed to investigate pituitary function before and up to five years after transsphenoidal surgery with emphasis on the hypothalamic-pituitary-adrenal axis (HPA).
DESIGN AND METHODS: Data from the Swedish Pituitary Register was used to analyze anterior pituitary function in 838 patients with NFPA diagnosed between 1991 and 2014. Patients who were reoperated or had received radiotherapy were excluded.
RESULTS: Preoperative ACTH, TSH, LH/FSH and GH deficiencies were reported in 31% (236/755), 39% (300/769), 51% (378/742) and 28% (170/604) of the patients, respectively. Preoperative median tumor volume was 5.0 (2.4-9.0) cm3. Amongst patients with preoperative, one year and five years postoperative data on the HPA axis (n=428), 125 (29%) were ACTH-deficient preoperatively. One year postoperatively, 26% (32/125) of them had recovered ACTH function while 23% (70/303) patients had developed new ACTH deficiency. Thus, one year postoperatively 163 (38%) patients were ACTH-deficient (P <0.001 vs. preoperatively). No further increase was seen five years postoperatively (36%, P=0.096). At one year postoperatively recoveries in the TSH- and LH/FSH-axes were reported in 14% (33/241) and 15% (46/310), respectively, and new deficiencies in 22% (88/403) and 29% (83/288), respectively.
CONCLUSIONS: ACTH deficiency increased significantly at one year postoperatively. Event though not significant, some patients recovered from or developed new deficiency between one and five years postoperatively. This pattern was seen in all axes. Our study emphasizes that continuous individual evaluations are needed during longer follow-up of patients operated for NFPA.
DESIGN AND METHODS: Data from the Swedish Pituitary Register was used to analyze anterior pituitary function in 838 patients with NFPA diagnosed between 1991 and 2014. Patients who were reoperated or had received radiotherapy were excluded.
RESULTS: Preoperative ACTH, TSH, LH/FSH and GH deficiencies were reported in 31% (236/755), 39% (300/769), 51% (378/742) and 28% (170/604) of the patients, respectively. Preoperative median tumor volume was 5.0 (2.4-9.0) cm3. Amongst patients with preoperative, one year and five years postoperative data on the HPA axis (n=428), 125 (29%) were ACTH-deficient preoperatively. One year postoperatively, 26% (32/125) of them had recovered ACTH function while 23% (70/303) patients had developed new ACTH deficiency. Thus, one year postoperatively 163 (38%) patients were ACTH-deficient (P <0.001 vs. preoperatively). No further increase was seen five years postoperatively (36%, P=0.096). At one year postoperatively recoveries in the TSH- and LH/FSH-axes were reported in 14% (33/241) and 15% (46/310), respectively, and new deficiencies in 22% (88/403) and 29% (83/288), respectively.
CONCLUSIONS: ACTH deficiency increased significantly at one year postoperatively. Event though not significant, some patients recovered from or developed new deficiency between one and five years postoperatively. This pattern was seen in all axes. Our study emphasizes that continuous individual evaluations are needed during longer follow-up of patients operated for NFPA.
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app